What 111,000 Women Taught Researchers About Breast Cancer Risk

A massive study links metabolic health to breast cancer risk.

Konoly Konoly
Jun 24, 2026 - 17:15
0 7
What 111,000 Women Taught Researchers About Breast Cancer Risk

Here's Why You Decolletage Shows Signs of Aging and How To Help

Image by Leah Flores / Stocksy

June 24, 2026

You've probably heard a lot about GLP-1 drugs lately (Ozempic, Wegovy, Mounjaro).

They started as diabetes medications, became blockbuster weight-loss drugs, and now researchers are asking a new question: could they also have something to do with breast cancer risk?

A new study looked at health records from more than 111,000 women to find out. The findings held up even after researchers accounted for BMI, age, breast density, and diabetes status.

About the study

The researchers wanted to know whether women prescribed GLP-1 receptor agonists (the drug class that includes semaglutide and tirzepatide), had different breast cancer detection rates than women who weren't.

They focused specifically on women with overweight or obesity, since excess weight is already a known risk factor for breast cancer.

Using electronic health records from January 2022 to June 2025, they identified 111,646 women between the ages of 45 and 80 who had a BMI of 25 or higher and had undergone breast imaging.

To make the comparison as clean as possible, they carefully matched GLP-1 users with non-users who were similar in age, race, ethnicity, BMI, breast density, and diabetes history; the groups were as comparable as possible before the analysis began.

The connection between metabolic health and breast cancer risk is what made this a compelling research question. Excess body fat, especially around the abdomen, tends to raise circulating estrogen levels, elevate insulin, and drive low-grade inflammation, all of which have been linked to breast cancer development.

GLP-1 drugs work partly by improving how the body handles blood sugar and reducing inflammation, which is why researchers are now asking whether those effects might extend beyond metabolic conditions.

GLP-1 users had roughly 30% lower breast cancer incidence

In the matched analysis (which included 30,528 observations and 600 cancer cases), women who used GLP-1 drugs had roughly 30% lower breast cancer incidence compared to matched non-users.

That difference held up independent of age, race, ethnicity, BMI, breast density, and diabetes status, which makes it a meaningful signal across a large and diverse group of women.

Women prescribed GLP-1 drugs may differ from non-users in ways not fully captured in the data, such as health-seeking behaviors, access to care, or other lifestyle factors. The researchers themselves are calling for longer-term, prospective trials to dig deeper.

Why metabolic health may matter more than weight alone

The connection between metabolic health and breast cancer isn't new, but this study adds to a growing body of evidence that the relationship is more nuanced than "excess weight raises risk."

When you carry excess body fat, especially around the abdomen, your body tends to produce more estrogen (fat tissue can convert other hormones into estrogen), pump out more insulin, and run a low-grade inflammatory state.

All three have been linked to breast cancer development and progression. GLP-1 drugs work partly by improving blood sugar regulation and dialing down inflammation, which may help explain why the risk reduction in this study appeared to go beyond BMI changes alone.

It may not just be about the number on the scale. How your body regulates blood sugar, manages inflammation, and handles hormones could all play a role in breast cancer risk in ways that weight alone doesn't fully capture.

How to support the same metabolic pathways through everyday habits

GLP-1 medications are not approved for cancer prevention, and this study doesn't change that.

But the metabolic pathways they influence (blood sugar regulation, inflammation, body composition) are ones you can meaningfully support through everyday habits, no prescription required.

A few evidence-informed levers worth knowing about:

Gradual weight loss if needed: Even modest reductions of around 5 to 10% of body weight can improve how your body handles blood sugar and lower circulating estrogen. Slow, sustainable loss tends to preserve muscle mass better than aggressive restriction.
Resistance training plus regular walking: Strength training two to three times per week improves blood sugar regulation and supports lean muscle, which plays a key role in how your body processes glucose. Pairing it with daily walking compounds the benefit.
Pairing carbs with protein, fat, and fiber: This slows how quickly glucose enters your bloodstream and blunts the insulin spike that follows a meal, one of the more practical ways to support metabolic health without overhauling your entire diet.
Prioritizing fiber-rich whole foods daily: Vegetables, legumes, and whole grains support gut health, help your body clear excess estrogen (fiber plays a role in estrogen excretion), and can reduce inflammatory markers over time.

The takeaway

This study doesn't mean GLP-1 drugs should be prescribed for breast cancer prevention; the evidence isn't there yet, and the researchers are clear about that.

What it does suggest is that metabolic health may be a more significant driver of breast cancer risk than previously appreciated, and that the relationship goes beyond BMI as a standalone measure.

The daily habits that support metabolic health—moving your body, eating fiber-rich whole foods, steadying blood sugar—may matter more for long-term cancer risk than we've given them credit for.